Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AKRO vs ALEC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALEC Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

ALEC Overall Winner 6-Pillar Tally: AKRO 0 – 6 ALEC Matrix Metrics: AKRO 4 – 6 ALEC

As of Nov 20, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas ALEC carries 52.1/100 (HOLD) at $2.33 (8.5x Forward P/E, 21.8% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. ALEC 52.1/100 HOLD), ALEC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (21.8% vs. 0.0% operating margin) and revenue trajectory (+4895.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs ALEC
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
ALEC NASDAQ Head-to-Head Winner
Alector, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.33
+1.52% 1D
Market Cap $342.4M
TTM Revenue $173M
Forward P/E 8.5x
Beta / 30D Vol 1.53β · 98% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 39.0 Fund 52.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $2.32 · SMA50: $2.09

6-Pillar Scorecard Institutional Category Breakdown (AKRO 0 – 6 ALEC)

Columns: Metric · AKRO · ALEC
1. Valuation Multiples ALEC
Forward P/E N/M 8.5x
Trailing P/E N/M 6.2x
PEG Ratio N/M N/M
EV / Revenue N/M 1.7x
2. Growth & Scale ALEC
Revenue Growth (YoY) +0.0% +4895.9%
Earnings Growth (YoY) +0.0% -86.3%
TTM Revenue (USD) N/A $173M
Market Cap $4.5B $342.4M
3. Profitability & Quality ALEC
Gross Margin N/A 42.5%
Operating Margin 0.0% 21.8%
Net Profit Margin 0.0% 23.9%
Return on Equity (ROE) -34.5% 47.5%
4. Balance Sheet & Cash Flow ALEC
Cash Generation (TTM) N/A -$150M
Cash Flow Margin N/A -86.5%
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $54M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALEC
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 7.3% (30th %ile) 152.6% (18th %ile)
Put/Call OI Skew N/A 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ALEC
OpEx & R&D Intensity N/A 20.7% of Rev ($36M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (4) vs ALEC (6)
Institutional Metric AKRO ALEC Criterion Row Edge
Market Capitalization
Scale
$4.5B $342.4M Larger Scale AKRO
Trailing P/E Ratio
Valuation
N/M 6.2x Lower Multiple ALEC
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple ALEC
Revenue Growth (YoY)
Growth
+0.0% +4895.9% Higher Growth ALEC
Operating Margin (TTM)
Profitability
0.0% 21.8% Higher Margin ALEC
Net Profit Margin
Profitability
0.0% 23.9% Higher Margin ALEC
Return on Equity (ROE)
Capital Efficiency
-34.5% 47.5% Higher ROE ALEC
52-Week Range Position
Momentum
90% ($21–$58) 71% ($1–$3) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol 1.53β · 98% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 52.1 / 100 (HOLD) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $173M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 42.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) -$150M ($54M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +0.57 pp
AKRO: +0.57% · ALEC: +0.0%
3M Horizon AKRO +0.57 pp
AKRO: +0.57% · ALEC: +0.0%
6M Horizon AKRO +0.57 pp
AKRO: +0.57% · ALEC: +0.0%
1Y Horizon AKRO +0.57 pp
AKRO: +0.57% · ALEC: +0.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs ALEC. Trailing 12-month operating profitability (AKRO 0.0% vs ALEC 21.8%) and valuation multiples (AKRO N/M vs ALEC 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
ALEC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$173M
Gross Margin42.5%
Op. Margin21.8%
ROE / Fwd P/E47.5% · 8.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALEC CONSOLIDATION
56d in phase · OBV NEUTRAL
Current IV 152.6%
IV Percentile 18th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ALEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ALEC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $342.4M market capitalization and 21.8% operating margin.
OpEx & R&D Reinvestment 20.7% of Rev ($36M)
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs ALEC Key Questions & Quantitative Answers

As of Nov 20, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas ALEC carries 52.1/100 (HOLD) at $2.33 (8.5x Forward P/E, 21.8% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. ALEC 52.1/100 HOLD), ALEC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (21.8% vs. 0.0% operating margin) and revenue trajectory (+4895.9% vs. +0.0% YoY).

ALEC leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ALEC at +4895.9% YoY revenue growth and -86.3% YoY earnings growth on $173M TTM revenue (42.5% gross margin, 21.8% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $173M for ALEC. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 20.7% of Rev ($36M) (0 disclosures) for ALEC.

ALEC screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ALEC trades at 8.5x Forward P/E, 6.2x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-86.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus ALEC (47.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, ALEC carries 152.6% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.53β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.